Cargando…

Potent therapeutic activity of folate receptor-targeted liposomal carboplatin in the localized treatment of intraperitoneally grown human ovarian tumor xenograft

Intraperitoneal (IP) therapy with platinum (Pt)-based drugs has shown promising results clinically; however, high locoregional concentration of the drug could lead to adverse side effects. In this study, IP administration was coupled with a folate receptor-targeted (FRT) liposomal system, in an atte...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chaudhury, Anumita, Das, Surajit, Bunte, Ralph M, Chiu, Gigi NC
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2012
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3282613/ https://www.ncbi.nlm.nih.gov/pubmed/22359453 http://dx.doi.org/10.2147/IJN.S26172

Ejemplares similares

Intraperitoneal chemotherapy in the management of ovarian cancer: focus on carboplatin
por: Markman, Maurie
Publicado: (2009)

Folate receptor targeting of radiolabeled liposomes reduces intratumoral liposome accumulation in human KB carcinoma xenografts
por: Christensen, Esben, et al.
Publicado: (2018)

Comparison of paclitaxel liposomes combined with carboplatin versus paclitaxel combined with carboplatin in the treatment of advanced ovarian cancer
por: Tan, Xiangbin, et al.
Publicado: (2023)

Therapy of human ovarian cancer xenografts with intraperitoneal liposome encapsulated muramyl-tripeptide phosphoethanolamine (MTP-PE) and recombinant GM-CSF.
por: Malik, S. T., et al.
Publicado: (1991)

Comparison of Neoadjuvant Chemotherapy Efficiency in Advanced Ovarian Cancer Patients Treated With Paclitaxel Plus Carboplatin and Intraperitoneal Bevacizumab vs. Paclitaxel With Carboplatin
por: Tao, Yin, et al.
Publicado: (2022)

Pharmacokinetics and toxicity of carboplatin used for hyperthermic intraperitoneal chemotherapy (HIPEC) in treatment of epithelial ovarian cancer
por: Mikkelsen, Mette Schou, et al.
Publicado: (2020)

Long-Term Survival Analysis of Intraperitoneal versus Intravenous Chemotherapy for Primary Ovarian Cancer and Comparison between Carboplatin- and Cisplatin-based Intraperitoneal Chemotherapy
por: Eoh, Kyung Jin, et al.
Publicado: (2017)

The Role of Intraperitoneal Carboplatin as Consalidation Chemotherapy in Women with Ovarian Carcinoma: Report of Our Experience and Systematic Review
por: Mousavi, Azamsadat, et al.
Publicado: (2016)

A phase I and pharmacokinetic study of intraperitoneal carboplatin and etoposide.
por: McClay, E. F., et al.
Publicado: (1993)

Double-Emulsion Copolyester Microcapsules for Sustained Intraperitoneal Release of Carboplatin
por: Cymbaluk-Płoska, Aneta, et al.
Publicado: (2019)

Anticancer activity of the intraperitoneal-delivered DFP-10825, the cationic liposome-conjugated RNAi molecule targeting thymidylate synthase, on peritoneal disseminated ovarian cancer xenograft model
por: Iizuka, Kenzo, et al.
Publicado: (2018)

Intraperitoneal Rupture of Ovarian Cysts
por: Das, Kedarnath
Publicado: (1901)

Successful local regional therapy with topotecan of intraperitoneally growing human ovarian carcinoma xenografts.
por: Pratesi, G., et al.
Publicado: (1995)

Co-delivery of carboplatin and paclitaxel via cross-linked multilamellar liposomes for ovarian cancer treatment
por: Zhang, Xiaoyang, et al.
Publicado: (2017)

Hypocrellin B‐loaded, folate‐conjugated polymeric micelle for intraperitoneal targeting of ovarian cancer in vitro and in vivo
por: Li, Jie, et al.
Publicado: (2018)

Radiolabeled liposome imaging determines an indication for liposomal anticancer agent in ovarian cancer mouse xenograft models
por: Ito, Ken, et al.
Publicado: (2015)

Effects of intraperitoneal recombinant interleukin-1 beta in intraperitoneal human ovarian cancer xenograft models: comparison with the effects of tumour necrosis factor.
por: Malik, S. T., et al.
Publicado: (1992)

Retrospective Analysis Of Comparative Outcomes In Recurrent Platinum-Sensitive Ovarian Cancer Treated With Pegylated Liposomal Doxorubicin (Lipo-Dox) And Carboplatin Versus Paclitaxel And Carboplatin
por: Weng, Chia-Sui, et al.
Publicado: (2019)

Impact of PEGylated Liposomal Doxorubicin and Carboplatin Combination on Glioblastoma
por: Ghaferi, Mohsen, et al.
Publicado: (2022)

Effect of Cerenkov Radiation-Induced Photodynamic Therapy with (18)F-FDG in an Intraperitoneal Xenograft Mouse Model of Ovarian Cancer
por: Chen, Yi-An, et al.
Publicado: (2021)

Phase II study of intraperitoneal submicron particle paclitaxel (SPP) plus IV carboplatin and paclitaxel in patients with epithelial ovarian cancersurgery
por: Mullany, Sally, et al.
Publicado: (2020)

Response of peritoneal solid tumours after intraperitoneal chemohyperthermia treatment with cisplatin or carboplatin.
por: Los, G., et al.
Publicado: (1994)

Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients
por: Wagner, U, et al.
Publicado: (2012)

Functional coating of liposomes using a folate– polymer conjugate to target folate receptors
por: Watanabe, Kazuo, et al.
Publicado: (2012)

Potent Inhibitory Effect of δ-Tocopherol on Prostate Cancer Cells Cultured in Vitro and Grown As Xenograft Tumors in Vivo
por: Huang, Huarong, et al.
Publicado: (2014)

Formulation Strategies for Folate-Targeted Liposomes and Their Biomedical Applications
por: Kumar, Parveen, et al.
Publicado: (2019)

Enzymatic synthesis and in vitro evaluation of folate-functionalized liposomes
por: Guo, Bohong, et al.
Publicado: (2017)

Maintenance of pegylated liposomal doxorubicin/carboplatin in patients with advanced ovarian cancer: randomized study of an Asian Gynecologic Oncology Group
por: Lai, Chyong-Huey, et al.
Publicado: (2019)

Folate Receptor Targeted Photodynamic Therapy: A Novel Way to Stimulate Anti-Tumor Immune Response in Intraperitoneal Ovarian Cancer
por: Baydoun, Martha, et al.
Publicado: (2023)

Imaging of Treatment Response to the Combination of Carboplatin and Paclitaxel in Human Ovarian Cancer Xenograft Tumors in Mice Using FDG and FLT PET
por: Munk Jensen, Mette, et al.
Publicado: (2013)

A Novel Salt Inducible Kinase 2 Inhibitor, ARN-3261, Sensitizes Ovarian Cancer Cell Lines and Xenografts to Carboplatin
por: Fan, Dengxuan, et al.
Publicado: (2021)

A phase 2 study of intraperitoneal carboplatin plus intravenous dose-dense paclitaxel in front-line treatment of suboptimal residual ovarian cancer
por: Hasegawa, Kosei, et al.
Publicado: (2020)

A phase I dose-finding study of a combination of pegylated liposomal doxorubicin (Doxil), carboplatin and paclitaxel in ovarian cancer
por: Gibbs, D D, et al.
Publicado: (2002)

Phase 1b safety study of farletuzumab, carboplatin and pegylated liposomal doxorubicin in patients with platinum-sensitive epithelial ovarian cancer(,,)
por: Kim, Kenneth H., et al.
Publicado: (2015)

Enhanced Antiproliferative Effect of Carboplatin in Cervical Cancer Cells Utilizing Folate-Grafted Polymeric Nanoparticles
por: Ji, Jing, et al.
Publicado: (2015)

The PARP1 Inhibitor AZD5305 Impairs Ovarian Adenocarcinoma Progression and Visceral Metastases in Patient-derived Xenografts Alone and in Combination with Carboplatin
por: Dellavedova, Giulia, et al.
Publicado: (2023)

[(18)F]-Fluorinated Carboplatin and [(111)In]-Liposome for Image-Guided Drug Delivery
por: Lamichhane, Narottam, et al.
Publicado: (2017)

A randomized phase II study of carboplatin plus pegylated liposomal doxorubicin versus carboplatin plus paclitaxel in platinum sensitive ovarian cancer patients: a Hellenic Cooperative Oncology Group study
por: Bafaloukos, Dimitrios, et al.
Publicado: (2010)

HER2-Specific Targeted Toxin DARPin-LoPE: Immunogenicity and Antitumor Effect on Intraperitoneal Ovarian Cancer Xenograft Model
por: Sokolova, Evgeniya A., et al.
Publicado: (2019)

Cisplatin/carboplatin cross-resistance in ovarian cancer.
por: Gore, M. E., et al.
Publicado: (1989)

Cannot write session to /tmp/vufind_sessions/sess_h5d0ofe7h5370iaeia2no5ip30